莫桑比克与坦桑尼亚床旁早期婴儿HIV诊断的成本效果比较
该研究嵌套于莫桑比克和坦桑尼亚28家基层医疗机构的整群随机LIFE试验,比较床旁出生时加4-8周检测(VEID)与仅4-8周标准检测(SoC)的成本效果。VEID成本更高但提前了ART启动,两国ICER分别为2924和10458美元,敏感性受宫内传播率影响。基于盈亏平衡分析,VEID需每额外早期ART启动获得6-32生命年才达标准阈值,当前价格下不太可能具成本效果。
要点
- VEID较SoC提高一周内ART启动比例,莫桑比克增90.0个百分点,坦桑尼亚增59.9个百分点。
- VEID每名HIV感染婴儿增量成本:莫桑比克2632美元,坦桑尼亚6263美元。
- ICER为莫桑比克2924美元、坦桑尼亚10458美元,对宫内传播率敏感。
核心结论
- 加出生检测改善早期ART启动,但当前价格和传播率下相对标准阈值不太可能具成本效果。
研究设计与样本
- 预设二次分析嵌套于莫桑比克和坦桑尼亚28家基层医疗机构的整群随机LIFE试验,2019年10月至2021年9月。
- 比较床旁出生加4-8周检测(VEID)与仅4-8周标准检测(SoC),均立即启动ART。
- 使用贝叶斯分层模型评估一周内ART启动的成本效果。
主要发现
- 莫桑比克VEID提高一周内ART启动90.0个百分点(95% CrI 67.5至98.5),每名HIV感染婴儿增量成本2632美元(95% CrI 2249至3062)。
- 坦桑尼亚VEID提高早期ART启动59.9个百分点(95% CrI 20.9至89.5),增量成本6263美元(95% CrI 5394至7243)。
- ICER在莫桑比克为2924美元、坦桑尼亚为10458美元,对宫内传播率敏感。
关键数值与推荐
- VEID需每额外早期ART启动获得6-32生命年才能达到标准阈值(盈亏平衡分析)。
临床怎么用
- 当前价格下VEID不太可能具成本效果,但若早期ART带来显著长期健康收益或靶向高垂直传播风险婴儿,可实现成本效果。
局限性
- 缺乏长期健康结局数据,依赖中间结局,ICER不能直接与基于生命年的阈值比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Timely access to early infant diagnosis (EID) is crucial for newborns with HIV, as late diagnosis can delay lifesaving antiretroviral treatment (ART). We assessed the comparative cost and cost-effectiveness of integrating point-of-care EID at birth into routine care in primary healthcare settings. METHODS AND FINDINGS: This pre-specified secondary analysis was nested in the cluster-randomized LIFE study conducted at 28 primary healthcare facilities in Mozambique and Tanzania from October 2019 to September 2021. We estimated the health system cost of point-of-care birth plus 4-8-week HIV testing (very early infant diagnosis; VEID) compared to standard-of-care (SoC) testing at 4-8 weeks only, both with immediate ART initiation. We assessed the cost-effectiveness of VEID relative to SoC with respect to ART initiation within one week of life using Bayesian hierarchical models. As this is an intermediate outcome, incremental cost-effectiveness ratios (ICERs) cannot be directly compared to available life-year-based cost-effectiveness thresholds. To contextualize results, we derived the minimum life-years gained per early ART initiation required for VEID to meet standard thresholds in a break-even analysis. VEID was associated with a higher cost and resulted in earlier ART initiation than SoC in both countries. In Mozambique, VEID increased the proportion of infants initiating ART within one week of life by 90.0 (95% CrI [67.5, 98.5]) percentage points at an incremental cost of $2,632 (95% CrI [$2,249, $3,062]) per infant with HIV. In Tanzania, VEID increased early ART initiation by 59.9 (95% CrI [20.9, 89.5]) percentage points at an incremental cost of $6,263 (95% CrI [$5,394, $7,243]) per infant with HIV. The ICER was $2,924 and $10,458 in Mozambique and Tanzania, respectively and was sensitive to intrauterine transmission rate. These findings were limited by the lack of long-term health outcome data and reliance on an intermediate outcome. Based on the break-even analysis, we estimated that VEID would need to yield 6-32 life-years gained per additional early ART initiation to meet standard thresholds. CONCLUSIONS: Adding birth testing improved early ART initiation but was unlikely to be cost-effective relative to standard thresholds given current prices, vertical transmission rates, and knowledge of long-term health benefits. Cost-effectiveness could be achieved at current costs if early ART translates to substantial long-term health benefits or if targeted to infants at high risk of vertical transmission.
引用
- Elsbernd K, Sabi I, Jani IV, et al. Point-of-care early infant HIV diagnosis at birth in a pragmatic cluster-randomized trial in Mozambique and Tanzania: A comparative cost and cost-effectiveness study. PLoS Med. 2026. PMID: 42090430. doi:10.1371/journal.pmed.1005069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。